ClinicalTrials.gg
CompletedNCT01777321Updated Oct 25, 2018Results posted

Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years

A Phase 3 interventional study of Herpes zoster vaccine GSK1437173A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 1 site in Japan. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-25.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
41st of 46
60 · median 239
Started
2013
with 3 others
Phase 3
22 of 46
2 open now
Registered
9th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 41st largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 9th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of GSK Biologicals' Herpes Zoster (HZ) vaccine (GSK 1437173A) when administered subcutaneously (SC) as compared to intramuscularly (IM) to people 50 years of age and older.

Read the detailed description

There are 2 treatment groups in this study based upon the mode of vaccine administration.

The humoral immunogenicity (HI) will be measured in all subjects.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Herpes Zoster
  • Intramuscular
  • Subcutaneous
  • Safety
  • ≥50 years of age
  • Adults
  • Immunogenicity
  • Elderly
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Subject, residing in Japan, is of Japanese ethnic origin, defined as having been born in Japan with four ethnic Japanese grandparents and able to speak Japanese.
  • Subject has provided written .
  • Subject, male or female, who is 50 YOA or older at the time of the first vaccination.
  • Subject, if female, of non- may be enrolled in the study.
  • Subject, if female, of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series (i.e., for 2 months after Month 2).

Exclusion criteria

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Concurrently participating or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Administration or planned administration of a within 30 days prior to the first study vaccination through 30 days after the second study vaccination.
  • Administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
  • Planned administration, during the study, of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
  • Administration of immunoglobulins and/or any blood products within the three (3) months preceding the first dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as >14 consecutive days) of or other immune-modifying drugs within six months prior to the first vaccine dose.

    • For , a prednisone dose of \<20 mg/day, or equivalent, is allowed.
    • Inhaled, topical, and intra-articular corticosteroids are allowed.
  • Administration or planned administration of long-acting immune-modifying drugs (e.g., infliximab) within six months prior to the first vaccine dose through the duration of the study period.
  • History of HZ.
  • Previous vaccination against HZ or varicella (registered or investigational product).
  • History of any reaction or likely to be exacerbated by any component of the vaccine or study material and equipment.
  • Significant underlying illness that, in the opinion of the investigator, would be expected to prevent completion of the study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • Acute disease and/or fever at the time of vaccination:

    • Fever is defined as temperature ≥37.5°C (99.5°F) for oral, axillary, or tympanic route, or ≥38.0°C/100.4°F for rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions (if of ) through Month 4 (i.e., 2 months after the second dose of study vaccine).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    SC HZ/su Group

    Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.

    Biological: Herpes zoster vaccine GSK1437173A

  • Active comparator
    IM HZ/su Group

    Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.

    Biological: Herpes zoster vaccine GSK1437173A

Interventions

  • HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)

    A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value, of 18 mIU/mL.

    Time frame: Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)

  2. Anti-gE Antibody Concentrations

    Anti-gE antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.

    Time frame: Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)

  3. Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations

    Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x18 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

    Time frame: At two months after Dose 1 (M2) and one month after Dose 2 (M3)

  4. Descriptive Statistics of Anti-gE Antibody Concentrations

    Anti-gE antibody concentrations were assessed by the Enzyme Lynked Immunosorbent Assay.

    Time frame: Before vaccination (PRE), at two months after dose 1 (M2) and one month after Dose 2 (M3)

  5. Number of Subjects With Solicited Local Symptoms

    The solicited local symptoms assessed were: Arm movement/range of motion of the vaccinated arm, Injection site pruritus, Pain, Redness, and Swelling. Any = occurrence of any local symptom regardless of their intensity grade. Grade 3 Pain = Significant pain at rest that prevented normal every day activities. Grade 3 Injection site pruritus = Significant pruritus that prevented normal every day activities. Grade 3 impairment of arm movement/range of motion = Significant impairment of arm movement/range of motion that prevented normal every day activities.

    Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses

  6. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were: Fatigue, Fever, Gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), Headache, Myalgia, and Shivering. Fever = axillary temperature ≥37.5°C. Any = occurrence of any general symptoms regardless of their intensity grade or relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 Fever = axillary temperature higher than (\>) 39.0°C. Related = general symptom assessed by the investigator as causally related to vaccination.

    Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses

  7. Mean Number of Days With Local Symptoms

    Days with solicited local symptoms were tabulated for the total vaccinated cohort.

    Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D)

  8. Mean Number of Days With General Symptoms

    Days with solicited general symptoms were tabulated for the total vaccinated cohort.

    Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D)

  9. Number of Subjects With Potential Immune-Mediated Disorders (pIMDs)

    Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From Month 0 to Month 3

  10. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within 30 days (Days 0-29) post vaccination period

  11. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Month 0 to Month 3

Secondary outcomes

  1. Number of Subjects With Anti-gE Antibody Concentrations ≥ 97 mIU/mL

    A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value of 97 mIU/mL.

    Time frame: At Month 14

  2. Anti-gE Antibody Concentrations

    Anti-gE antibody concentrations were expressed as geometric mean concnetrations (GMCs) and measured in mIU/mL.

    Time frame: At Month 14

  3. Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations

    Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

    Time frame: Twelve Months after Dose 2 (M14)

  4. Number of Subjects With pIMDs

    Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: Up to Month 14 post vaccination period

  5. Number of Subjects With SAEs

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Up to Month 14 post vaccination period

07

Results

Posted Jan 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneSC GSK1437173A GroupIM GSK1437173A Group
Started3030
Completed3029
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)

A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value, of 18 mIU/mL.

Time frame:
Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Anti-gE, PRE2929
Anti-gE, M22929
Anti-gE, M32929
PrimaryAnti-gE Antibody Concentrations

Anti-gE antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.

Time frame:
Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations
mIU/mLSC GSK1437173A GroupIM GSK1437173A Group
Anti-gE, PRE1424.3 (1042.6 to 1945.6)1116.8 (774.5 to 1610.3)
Anti-gE, M219902.5 (14846.9 to 26679.6)12842 (8558.4 to 19269.7)
Anti-gE, M344126.1 (36326.1 to 53601)45521.5 (37549.5 to 55185.9)
PrimaryNumber of Subjects With Vaccine Response for Anti-gE Antibody Concentrations

Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x18 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

Time frame:
At two months after Dose 1 (M2) and one month after Dose 2 (M3)
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Anti-gE, M22825
Anti-gE, M32929
PrimaryDescriptive Statistics of Anti-gE Antibody Concentrations

Anti-gE antibody concentrations were assessed by the Enzyme Lynked Immunosorbent Assay.

Time frame:
Before vaccination (PRE), at two months after dose 1 (M2) and one month after Dose 2 (M3)
Reported as:
Median · mIU/mL
Descriptive Statistics of Anti-gE Antibody Concentrations
mIU/mLSC GSK1437173A GroupIM GSK1437173A Group
Anti-gE, PRE1404.1 ± 1398.82946.3 ± 3231.78
Anti-gE, M219400.1 ± 24456.8614330.1 ± 14548.75
Anti-gE, M344182 ± 27990.9942444.8 ± 27555.21
PrimaryNumber of Subjects With Solicited Local Symptoms

The solicited local symptoms assessed were: Arm movement/range of motion of the vaccinated arm, Injection site pruritus, Pain, Redness, and Swelling. Any = occurrence of any local symptom regardless of their intensity grade. Grade 3 Pain = Significant pain at rest that prevented normal every day activities. Grade 3 Injection site pruritus = Significant pruritus that prevented normal every day activities. Grade 3 impairment of arm movement/range of motion = Significant impairment of arm movement/range of motion that prevented normal every day activities.

Time frame:
During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Any Arm movement impairment, D1107
Any Arm movement impairment, D21611
Any Arm movement impairment, Across1812
Grade 3 Arm movement impairment, D110
Grade 3 Arm movement impairment, D200
Grade 3 Arm movement impairment, Across10
Any Injection site pruritus, D1196
Any Injection site pruritus, D2158
Any Injection site pruritus, Across2110
Grade 3 Injection site pruritus, D100
Grade 3 Injection site pruritus, D200
Grade 3 Injection site pruritus, Across00
Any Pain, D12826
Any Pain, D22521
Any Pain, Across2827
Grade 3 Pain, D120
Grade 3 Pain, D210
Grade 3 Pain, Across20
Any Redness, D12311
Any Redness, D22312
Any Redness, Across2615
Grade 3 Redness, D1121
Grade 3 Redness, D2121
Grade 3 Redness, Across172
Any Swelling, D1227
Any Swelling, D22011
Any Swelling, Across2412
Grade 3 Swelling, D181
Grade 3 Swelling, D261
Grade 3 Swelling, Across102
PrimaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were: Fatigue, Fever, Gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), Headache, Myalgia, and Shivering. Fever = axillary temperature ≥37.5°C. Any = occurrence of any general symptoms regardless of their intensity grade or relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 Fever = axillary temperature higher than (\>) 39.0°C. Related = general symptom assessed by the investigator as causally related to vaccination.

Time frame:
During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Any Fatigue, D11412
Any Fatigue, D2169
Any Fatigue, Across2116
Grade 3 Fatigue, D100
Grade 3 Fatigue, D201
Grade 3 Fatigue, Across01
Related Fatigue, D11412
Related Fatigue, D2169
Related Fatigue, Across2116
Any Fever/Axillary, D132
Any Fever/Axillary, D256
Any Fever/Axillary, Across67
Grade 3 Fever/Axillary, D100
Grade 3 Fever/Axillary, D200
Grade 3 Fever/Axillary, Across00
Related Fever/Axillary, D132
Related Fever/Axillary, D256
Related Fever/Axillary, Across67
Any Gastrointestinal symptoms, D124
Any Gastrointestinal symptoms, D253
Any Gastrointestinal symptoms, Across75
Grade 3 Gastrointestinal symptoms, D100
Grade 3 Gastrointestinal symptoms, D201
Grade 3 Gastrointestinal symptoms,Across01
Related Gastrointestinal symptoms, D124
Related Gastrointestinal symptoms, D253
Related Gastrointestinal symptoms,Across75
Any Headache, D1118
Any Headache, D21110
Any Headache, Across1713
Grade 3 Headache, D100
Grade 3 Headache, D202
Grade 3 Headache, Across02
Related Headache, D1118
Related Headache, D21110
Related Headache, Across1713
Any Myalgia, D121
Any Myalgia, D253
Any Myalgia, Across74
Grade 3 Myalgia, D110
Grade 3 Myalgia, D201
Grade 3 Myalgia, Across11
Related Myalgia, D121
Related Myalgia, D253
Related Myalgia, Across74
Any Shivering, D133
Any Shivering, D266
Any Shivering, Across87
Grade 3 Shivering, D101
Grade 3 Shivering, D200
Grade 3 Shivering, Across01
Related Shivering, D133
Related Shivering, D266
Related Shivering, Across87
PrimaryMean Number of Days With Local Symptoms

Days with solicited local symptoms were tabulated for the total vaccinated cohort.

Time frame:
During the 7 day (Days 0-6) post vaccination, after each dose (D)
Reported as:
Mean · Days
Mean Number of Days With Local Symptoms
DaysSC GSK1437173A GroupIM GSK1437173A Group
Days with arm movement, D13.9 (2 to 7)3 (2 to 3)
Days with pain, D13.3 (2 to 4)2.7 (2 to 3)
Days with injection site pruritus, D15.2 (2 to 7)2.2 (1 to 3)
Days with redness, D16.5 (4 to 8)2.6 (2 to 3)
Days with swelling, D15 (3 to 6)3 (2 to 3)
Days with arm movement, D22.9 (2 to 3)2.2 (2 to 3)
Days with pain, D23.4 (2 to 4)2.3 (1 to 3)
Days with injection site pruritus, D24.9 (3 to 5)1.9 (1.5 to 2)
Days with redness, D25.9 (3 to 6)3.7 (3 to 4)
Days with swelling, D24.3 (3 to 6)2.8 (2 to 4)
PrimaryMean Number of Days With General Symptoms

Days with solicited general symptoms were tabulated for the total vaccinated cohort.

Time frame:
During the 7 day (Days 0-6) post vaccination, after each dose (D)
Reported as:
Mean · Days
Mean Number of Days With General Symptoms
DaysSC GSK1437173A GroupIM GSK1437173A Group
Days with fatigue, D12.3 (1 to 3)2 (1 to 2)
Days with fever, D11.3 (1 to 2)1 (1 to 1)
Days with gastrointestinal symptoms, D12 (1 to 3)2 (2 to 2)
Days with headache, D11.8 (1 to 2)1.4 (1 to 2)
Days with myalgia, D16.5 (3 to 10)2 (2 to 2)
Days with Shivering, D11.3 (1 to 2)1.3 (1 to 2)
Days with fatigue, D22 (1 to 2)1.3 (1 to 2)
Days with fever, D21 (1 to 1)1 (1 to 1)
Days with gastrointestinal symptoms, D23.6 (2 to 5)1.3 (1 to 2)
Days with headache, D22 (1 to 2)1.3 (1 to 2)
Days with myalgia, D22 (1 to 2)1.3 (1 to 2)
Days with Shivering, D22.2 (1 to 2.2)1 (1 to 1)
PrimaryNumber of Subjects With Potential Immune-Mediated Disorders (pIMDs)

Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From Month 0 to Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Potential Immune-Mediated Disorders (pIMDs)
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Number of Subjects With Potential Immune-Mediated Disorders (pIMDs)00
PrimaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within 30 days (Days 0-29) post vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Any AEs96
Grade 3 AEs10
Related AEs11
PrimaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Month 0 to Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Number of Subjects With Serious Adverse Events (SAEs)10
SecondaryNumber of Subjects With Anti-gE Antibody Concentrations ≥ 97 mIU/mL

A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value of 97 mIU/mL.

Time frame:
At Month 14
Reported as:
Count of participants · Participants
Number of Subjects With Anti-gE Antibody Concentrations ≥ 97 mIU/mL
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Number of Subjects With Anti-gE Antibody Concentrations ≥ 97 mIU/mL3028
SecondaryAnti-gE Antibody Concentrations

Anti-gE antibody concentrations were expressed as geometric mean concnetrations (GMCs) and measured in mIU/mL.

Time frame:
At Month 14
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations
mIU/mLSC GSK1437173A GroupIM GSK1437173A Group
Anti-gE Antibody Concentrations15250.9 (12464 to 18660.9)13870.2 (10184.2 to 18890.3)
SecondaryNumber of Subjects With Vaccine Response for Anti-gE Antibody Concentrations

Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

Time frame:
Twelve Months after Dose 2 (M14)
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations2525
SecondaryNumber of Subjects With pIMDs

Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
Up to Month 14 post vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With pIMDs
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Number of Subjects With pIMDs00
SecondaryNumber of Subjects With SAEs

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Up to Month 14 post vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With SAEs
ParticipantsSC GSK1437173A GroupIM GSK1437173A Group
Number of Subjects With SAEs21

Adverse events

Collected over Solicited symptoms: during the 7-day post-vaccination period; Unsolicited AEs: during the 30-day post-vaccination period; SAEs: up to Month 14 post vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SC GSK1437173A Group0/30 (0%)2/30 (6.7%)30/30 (100%)
IM GSK1437173A Group0/30 (0%)1/30 (3.3%)28/30 (93.3%)
Most frequent serious events
Most frequent serious events
EventSC GSK1437173A GroupIM GSK1437173A Group
Spinal compression fractureInjury, poisoning and procedural complications0/301/30
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/300/30
Mallet fingerMusculoskeletal and connective tissue disorders1/300/30
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSC GSK1437173A GroupIM GSK1437173A Group
PainGeneral disorders28/3027/30
RednessGeneral disorders26/3015/30
SwellingGeneral disorders24/3012/30
Injection site pruritusGeneral disorders21/3010/30
FatigueGeneral disorders21/3016/30
Arm movementGeneral disorders18/3012/30
HeadacheGeneral disorders17/3013/30
ShiveringGeneral disorders8/307/30
Fever/(Axillary)General disorders6/307/30
Gastrointestinal symptomsGeneral disorders7/305/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SC GSK1437173A GroupIM GSK1437173A GroupTotal
Mean61.6 ± 7.5962.2 ± 7.8361.90 ± 7.65
Sex: Female, Male
Sex: Female, Male(Participants)SC GSK1437173A GroupIM GSK1437173A GroupTotal
Female151530
Male151530
08

Study locations

1 site
  • GSK Investigational Site
    Fukuoka, 812-0025, Japan
09

References and documents

Publications

  • Vink P, Shiramoto M, Ogawa M, Eda M, Douha M, Heineman T, Lal H. Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged >/=50 years when administered subcutaneously vs. intramuscularly. Hum Vaccin Immunother. 2017 Mar 4;13(3):574-578. doi: 10.1080/21645515.2016.1232787. Epub 2016 Dec 9. PubMed 27936344 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Oct 2013 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 3 years 2 months after primary completion. A results delay was requested in Dec 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2013
First posted
Jan 28, 2013
Start
Jun 17, 2013
Primary completionActual
Oct 10, 2013
CompletionActual
Nov 11, 2014
Results delay requested
Dec 5, 2013
Results first posted
Jan 6, 2017
Last update
Oct 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01777321
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 28, 2013
Start date
Jun 17, 2013
Primary completion
Oct 10, 2013
Completion
Nov 11, 2014
Results posted
Jan 6, 2017
Last update
Oct 25, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion